The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Biological profiling in CLL: which emerging markers are changing management?
Richard Rosenquist, MD, PhD, Karolinska Institute, Solna, Sweden, discusses the current state of biological profiling in chronic lymphocytic leukemia (CLL), highlighting established markers used in clinical practice and included in guidelines. Prof. Rosenquist notes that other markers, including complex karyotype and specific mutations like IGHV3-21 R110, are being researched and may have potential as prognostic tools, but require further definition and study. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
